← Oncology Approval Tracker

FDA DECISION ·

Tecartus

brexucabtagene autoleucel · Kite Pharma

FDA approvalNew or expanded indicationB-cell acute lymphoblastic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

LAMPGEN ANALYSIS

Why it matters

The decision expands a CD19 CAR T product into adult B-ALL.

What research teams should watch

Verify lineage and relapse status and plan bridging treatment and infusion timing around manufacturing.

PRIMARY RECORDS

Sources